WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) said it will present Phase 2 exploratory data on its investigational skin cancer treatment VP-315 at the 2026 Society for Investigative Dermatology Annual Meeting in Chicago.
The company said the late-breaking abstract, focused on basal cell carcinoma, will be presented May 15 during a poster session at the meeting, which runs May 13–16.
The presentation will highlight findings suggesting a potential abscopal effect, in which treatment of one tumor may trigger responses in untreated tumors.
VP-315 is an oncolytic peptide therapy administered directly into tumors to stimulate an immune response, the company said.
Verrica holds worldwide rights to develop and commercialize the therapy for certain dermatologic cancers, including basal cell carcinoma, squamous cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma.
Basal cell carcinoma is the most common form of cancer in the United States, with about 3.6 million cases diagnosed annually, according to the company.
Current treatment often involves surgical removal of tumors, which can result in complications such as pain, infection, and scarring.
Verrica said VP-315 has shown immune responses in earlier Phase 1/2 oncology trials and is being developed as a potential non-surgical treatment option.
The company also markets YCANTH (VP-102), an FDA-approved treatment for molluscum contagiosum, and is developing it for additional dermatological conditions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.